{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:07Z","timestamp":1782990007768,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Diagnosing myeloid sarcoma remains challenging, and we aimed to provide clinicopathological features to facilitate diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Clinicopathological data from 41 patients with de novo and 31 with secondary myeloid sarcoma were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most de novo cases presented with isolated myeloid sarcoma (n\u00a0=\u00a019) or myeloid sarcoma with concurrent acute myeloid leukemia (n\u00a0=\u00a015). Most secondary cases presented after acute myeloid leukemia (n\u00a0=\u00a011), myeloproliferative neoplasm (n\u00a0=\u00a09), or myelodysplastic syndrome (n\u00a0=\u00a08). Most frequent localizations were skin and lymph nodes. Immunohistochemistry showed immature and\/or aberrant antigenic expression in 29% of de novo and 39% of secondary cases. Most genetic abnormalities were <jats:italic><jats:styled-content style=\"fixed-case\">RUNX<\/jats:styled-content>1\u2010<jats:styled-content style=\"fixed-case\">RUNX<\/jats:styled-content>1T1<\/jats:italic> (n\u00a0=\u00a04), <jats:italic><jats:styled-content style=\"fixed-case\">CBFB<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MYH<\/jats:styled-content>11<\/jats:italic> (n\u00a0=\u00a02), <jats:italic><jats:styled-content style=\"fixed-case\">KMT<\/jats:styled-content>2A\u2010<jats:styled-content style=\"fixed-case\">MLLT<\/jats:styled-content>3<\/jats:italic> (n\u00a0=\u00a02), and <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2<\/jats:italic> V617F (n\u00a0=\u00a02) mutations in de novo myeloid sarcoma, and <jats:italic><jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content>1<\/jats:italic> (n\u00a0=\u00a05) and <jats:italic><jats:styled-content style=\"fixed-case\">KMT<\/jats:styled-content>2A<\/jats:italic> rearrangements (n\u00a0=\u00a02) in secondary cases. A complex karyotype was seen in 17% of de novo and 39% of secondary cases. Most prevalent treatment was induction chemotherapy followed by consolidation chemotherapy (n\u00a0=\u00a010) or allogeneic stem cell transplantation (n\u00a0=\u00a09) for de novo and radiotherapy (n\u00a0=\u00a011) for secondary cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>De novo myeloid sarcoma mostly presented isolated. Lesions were often localized at skin and lymph nodes. Genetic aberrations frequently involved core\u2010binding factor rearrangements in de novo cases and a complex karyotype in secondary cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13056","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T10:17:25Z","timestamp":1521109045000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-5592","authenticated-orcid":false,"given":"Helena","family":"Claerhout","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Aelst","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Melis","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospitals Leuven  Leuven Belgium"},{"name":"Translational Cell and Tissue Research KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gheysens","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospitals Leuven  Leuven Belgium"},{"name":"Center for Human Genetics KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Dierickx","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospitals Leuven  Leuven Belgium"},{"name":"Department of Oncology KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Boeckx","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine University Hospitals Leuven  Leuven Belgium"},{"name":"Department of Oncology KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"140","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Pileri SA","year":"2008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1ZA7HYZKAZHS"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711410774"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290012056"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.12.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7743"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5892"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000727"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPO58YWIBUBESX"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.06.014"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.001"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404491"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.01.022"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-2-42"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-R"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199809)31:3<144::AID-MPO3>3.0.CO;2-B"},{"key":"e_1_2_6_19_1","first-page":"245395","article-title":"Recurrence of a t(8;21)\u2010positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge","volume":"2013","author":"Di Veroli A","year":"2013","journal-title":"Case Rep Hematol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.9505"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402721"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23691"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0291-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.963080"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:17:17Z","timestamp":1695496637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/ejh.13056"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13056","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"2018-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}